Bridger Management LLC Acquires New Position in Eli Lilly and Company $LLY

Key Points

• Bridger Management acquired 5,845 Eli Lilly shares worth approximately $7.0 million, making LLY 4.7% of its portfolio and its sixth-largest holding. Institutional investors collectively own 82.53% of the company.
• Eli Lilly reported strong quarterly results, with revenue rising 47.7% year over year to $22.97 billion and EPS of $8.38, exceeding estimates. Analysts maintain a broadly bullish view, with a “Moderate Buy” consensus and an average price target of $1,292.18.
• Growth prospects include expanded cardiovascular-risk use for Mounjaro, positive Zepbound clinical data and the planned acquisition of Merida Biosciences; however, potential reductions in employer and insurer coverage for GLP-1 drugs remain a key risk.

Bridger Management LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 5,845 shares of the company's stock, valued at approximately $7,011,000. Eli Lilly and Company accounts for 4.7% of Bridger Management LLC's holdings, making the stock its 6th biggest holding.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Coastal Bridge Advisors LLC acquired a new position in Eli Lilly and Company in the second quarter worth approximately $2,959,000. Mosaic Family Wealth Partners LLC raised its position in Eli Lilly and Company by 70.6% during the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company's stock valued at $4,144,000 after acquiring an additional 1,430 shares in the last quarter. Generali Investments Management Co LLC lifted its stake in Eli Lilly and Company by 17.5% in the second quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company's stock valued at $12,258,000 after acquiring an additional 1,521 shares during the last quarter. Moran Wealth Management LLC grew its position in Eli Lilly and Company by 85.6% in the second quarter. Moran Wealth Management LLC now owns 20,903 shares of the company's stock worth $25,072,000 after acquiring an additional 9,638 shares in the last quarter. Finally, Amundi grew its position in Eli Lilly and Company by 9.9% in the first quarter. Amundi now owns 5,055,025 shares of the company's stock worth $4,649,464,000 after acquiring an additional 454,549 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA expands Mounjaro’s opportunity: The FDA approved Mounjaro (tirzepatide) to reduce cardiovascular risk in high-risk adults with type 2 diabetes, potentially broadening the drug’s eligible market and strengthening its value proposition in discussions with insurers. Mounjaro FDA approval
• Positive Sentiment: Durable Zepbound clinical data: One-year Phase 3b results showed that combining Zepbound with Taltz produced sustained or improved outcomes for adults with obesity and psoriasis or psoriatic arthritis. The results support additional immunometabolic applications for Zepbound and reinforce Lilly’s leadership in GLP-1 medicines. Zepbound and Taltz Phase 3b data
• Positive Sentiment: Pipeline diversification through Merida: Lilly agreed to acquire Merida Biosciences for up to $2.875 billion in cash. Merida’s antibody-engineering platform and lead Phase 1 candidate, MER511, target Graves’ disease and thyroid eye disease, with additional potential in food allergy and other immune-related conditions. The deal could help Lilly use GLP-1-generated cash flow to build growth beyond obesity and diabetes. Merida Biosciences acquisition
• Neutral Sentiment: Acquisition risk remains limited but tangible: Merida’s lead asset is still in Phase 1, so the deal’s value depends on future clinical success and milestone payments. Lilly plans to close the transaction in the fourth quarter of 2026. Merida deal Phase 1 risks
• Neutral Sentiment: Lilly will participate in the Morgan Stanley Global Healthcare Conference on September 14, which could provide updates on its pipeline, GLP-1 demand and acquisition strategy. Morgan Stanley healthcare conference
• Negative Sentiment: 2027 payer concerns remain an overhang: Reports indicate some employers and insurers may reduce GLP-1 coverage, potentially affecting future Zepbound pricing and demand. The new Mounjaro cardiovascular indication may help Lilly defend coverage for certain diabetes patients, but it does not eliminate broader reimbursement risk. GLP-1 insurance coverage concerns

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on LLY. Jefferies Financial Group raised their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a "buy" rating in a report on Tuesday, June 9th. Bank of America upped their price objective on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a "buy" rating in a report on Friday, July 10th. The Goldman Sachs Group reissued a "buy" rating and set a $1,283.00 target price on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Leerink Partners boosted their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an "outperform" rating in a research report on Thursday, June 25th. Finally, Wolfe Research reiterated an "outperform" rating and set a $1,350.00 price target on shares of Eli Lilly and Company in a research note on Thursday, May 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $1,292.18.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $1,159.53 on Wednesday. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The firm has a fifty day simple moving average of $1,191.34 and a 200-day simple moving average of $1,067.41. The stock has a market capitalization of $1.09 trillion, a price-to-earnings ratio of 38.91, a PEG ratio of 1.36 and a beta of 0.50. Eli Lilly and Company has a 1-year low of $712.05 and a 1-year high of $1,292.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company's revenue was up 47.7% compared to the same quarter last year. During the same period last year, the business posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, sell-side analysts expect that Eli Lilly and Company will post 36.35 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 23.22%.

Insider Activity

In related news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source